Castle Biosciences CSTL Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 79.4%-2.5pp | 81.9%+2.3pp | 79.5%+2.9pp | 76.6%-6.5pp | |
| Operating margin | -12.4%-15.0pp | 2.6%+33.5pp | -30.9%+22.2pp | -53.2%-10.6pp | |
| Net margin | -7%-12.5pp | 5.5%+31.6pp | -26.1%+22.8pp | -49%-15.7pp | |
| Returns | |||||
| Return on equity | -5.2%-9.5pp | 4.3%+18.8pp | -14.5%+2.0pp | -16.6%-9.0pp | |
| Return on invested capital | -11.4%-13.9pp | 2.6%+25.3pp | -22.8%+15.6pp | -38.3%— | |
| Efficiency | |||||
| Asset turnover | 0.6×-0.1× | 0.7×+0.2× | 0.5×+0.2× | 0.3×+0.1× | |
| Liquidity | |||||
| Current ratio | 5.3×-2.0× | 7.3×+1.1× | 6.2×-1.9× | 8.1×-6.1× | |
| Leverage | |||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | |||||
| Book value per share | $16.24+4.3% | $15.58+6.7% | $14.60-4.7% | $15.32-6.5% | |
| Valuation | |||||
| Market capitalization | $694.86M+29.9% | $746.39M+28.5% | $580.73M-6.4% | $620.32M-42.8% | |
| Price / sales | 2×+0.5× | 2.2×-0.4× | 2.6×-1.9× | 4.5×-7.0× | |
| Price / book | 1.5×+0.3× | 1.6×+0.2× | 1.5×-0.1× | 1.6×-1.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Castle Biosciences's profit margins?
- Castle Biosciences (CSTL) runs a 77.9% gross margin and a -9.8% operating margin, with a -3.8% net margin.
- Where do Castle Biosciences's ratios come from?
- Every ratio is computed from Castle Biosciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
